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Abstract 
Previous studies in this laboratory have indicated that E. coli Nissle 1917 can act as a probiotic 
and is able to prevent the pathogenic E. coli EDL933 from growing to high numbers in the mouse 
large intestine. This study evaluated the influence of gluconeogenesis in E. coli Nissle 1917 and 
E. coli EDL933 to compete against each other and for their maintenance in the intestine. 
Knockout mutants of both strains were created for the analysis of the importance of 
gluconeogenesis in colonization experiments in the mouse large intestine. To knock out the 
ability to use gluconeogenesis and therefore metabolizing substrates such as pyruvate, TCA cycle 
intermediates and amino acids, simultaneously both genes pckA, encoding for 
phosphoenolpyruvate carboxykinase, and ppsA, encoding for phosphoenolpyruvate synthetase, 
were replaced by a non-functional chloramphenicol cassette.  
It was shown that E. coli Nissle 1917 uses glycolysis and gluconeogenesis concurrently 
throughout colonization of the mouse large intestine. E. coli EDL933 utilized glycolysis 
exclusively when it was the only E. coli strain present, but switched to gluconeogenesis when it 
was in the presence of a competing E. coli strain. Knocking out the ability to use gluconeogenesis 
in E. coli EDL933, led to a severe disability to colonize the mouse large intestine when it 
competed against E. coli Nissle 1917 which used up most of the glycolytic substrates. By 
implication E. coli Nissle 1917 seems to use up most of the glycolytic substrates and some of the 
gluconeogenic substrates, E. coli EDL933 depends on utilizing gluconeogenic substrates to be 
able to maintain itself in the mouse large intestine. Phenotypic characterization of the usage of 
different substrates in E. coli Nissle 1917 and E. coli EDL933 strains revealed several differences 
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1 Goals of this Study  
Escherichia coli EDL933, an O157:H7 strain, is known to be a noninvasive enteric shiga toxin 
producing pathogen causing gastrointestinal illnesses including hemolytic uremic syndrome 
(HUS) and hemorrhagic colitis (HC) in humans [29, 51] and is ingested by eating undercooked 
food. Because humans are colonized with different commensal E. coli strains, differences in 
nutrient availability may provide open niches for E. coli pathogens in some individuals and a 
barrier to infection in others.  
Nowadays the well-established probiotic E. coli strain Nissle 1917 is used to treat different 
intestinal diseases. Prophylactic clinical colonization trials of E. coli Nissle 1917 in newborns have 
been conducted in Germany and Czech Republic [26]. The colonization trials show that 
intentional colonization of the newborn’s gut with E. coli Nissle 1917 or other commensal non-
pathogenic E. coli strains results in early induction of the immunologic competence of the gut-
associated lymphoid tissue (GALT). It also results in prevention of hospital-acquired infections 
and in prevention of colonization by unwanted bacteria such as multidrug resistant or 
pathogenic E. coli strains [26].  
Based on findings like these I decided to focus on the interaction of probiotic E. coli Nissle 1917 
and the pathogen E. coli EDL933 during their colonization of the mouse large intestine to better 
understand how E. coli Nissle 1917 acts as a probiotic. 
When competing against E. coli EDL933, E. coli Nissle 1917 is not yet able to outcompete this 
pathogen completely from the mouse intestine in vivo [33]. Little is known about nutrients that 
are utilized by E. coli Nissle 1917 for growth in the intestine or its metabolic pathways involved 
in competing against E. coli EDL933. If these pathways were defined, it would help in developing 
more efficient treatments for patients infected with O157:H7 strains. Therefore my focus lies on 
2 
 
generating an E. coli Nissle 1917 ΔpckA ΔppsA knockout mutant, which grows normally on 
glycolytic substrates but is unable to utilize tricarboxylic acid (TCA) cycle intermediates and 
gluconeogenic substrates for growth. In addition ability to colonize the mouse intestine in the 
presence of E. coli Nissle 1917 wild type as well as E. coli EDL933 was analyzed. The focus lays 
also on the importance of the glyoxylate shunt, the shortcut of the TCA cycle, as I analyze an E. 
coli Nissle 1917 ΔaceA knockout mutant and its ability to colonize the mouse intestine in the 
presence of E. coli Nissle 1917 wild type.  
Finally I define if there are differences in E. coli Nissle 1917, E. coli Nissle 1917 ΔpckA ΔppsA, E. 
coli EDL933 and E. coli EDL933 ΔpckA ΔppsA regarding their oxidation of 95 different carbon 
sources to clarify whether or not the presence of specific carbon sources in the intestine might 




2 Review of Literature 
2.1 General background of Escherichia coli. 
Escherichia coli belongs to the family Enterobacteriaceae and is the only member of the genus 
Escherichia [58].  Its appearance is a short gram-negative, non-sporing and fimbriate bacillus 
[58], which grows as a facultative anaerobe readily on simple culture media and synthetic media 
with glycerol or glucose as the sole carbon and energy source [58]. The primary habitat of E. coli 
is the gastro-intestinal tract and the bowel of mammals and birds. Natural colonization of 
commensal E. coli strains is known to take place soon after birth [5] and its source is to be found 
in the mother and in the environment [5]. Once established in the gastro-intestinal tract, E. coli 
still remains a minority member of the fecal flora. 
2.2 E. coli O157:H7 pathogenesis. 
Commensal E. coli strains are not harmful, however there are pathogenic E. coli strains, such as 
enterohemorrhagic Escherichia coli (EHEC) serotypes like E. coli EDL933 O157:H7 [45], a 
noninvasive enteric shiga toxin producing pathogen which is known to cause gastrointestinal 
illnesses like hemolytic uremic syndrome (HUS) and hemorrhagic colitis (HC) in humans [22, 25, 
29, 51] and is ingested by eating undercooked food. Serotype O157:H7 is the major source of 
reported E. coli food poisoning outbreaks in the United States (US) [28]. Shiga toxins produced 
by EHEC bacteria are thought to damage host endothelial cells in small vessels of the intestine, 
kidney and brain resulting in thrombotic microangiopathy [28]. 
Etienne-Mesmin et al., 2012 found new key steps in the pathogenesis of EHEC’s infection [13]. 
They postulated that many bacterial pathogens cross the intestinal barrier through microfold 
cells which are known to transport organisms and particles from the gut lumen to immune cells 
across the epithelial barrier, and thus are important in stimulating mucosal immunity. Once 
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passed through the microfold cells, EHEC cells are captured by mucosal macrophages. Since 
EHEC belongs to Shiga toxin (Stx) producing bacteria and is able to survive and to produce Stx 
within the macrophages, this translocation of Stx from the gut lumen to underlying tissues is a 
decisive step in the development of the infection. Following replication of bacteria in 
macrophages, their extensive Stx production induces macrophage cell death. Subsequently, 
released Stx can cross the downstream blood vessels to reach the kidneys, intestine, and the 
brain. Damage to these organs results in serious life-threatening complications in humans [13]. 
Njoroge et al. 2012 described a novel mechanism of regulation that links metabolism to 
pathogenesis [47]. The virulence strategy of EHEC to enter through enterocytes is to form 
attaching and effacing (AE) lesions on enterocytes (see Figure 1). The expression of most of the 
genes necessary for this enterocyte effacement requires the regulator Ler. Whereas growth 
within a glycolytic environment inhibits the expression of ler, growth within a gluconeogenic 
environment activates expression of these genes. This is achieved through two transcription 
factors calles KdpE and Cra, which directly bind to the ler promoter and are sugar-dependently 





Figure 1: EHEC infection in humans [13]. It is illustrated how EHEC bacteria cross the intestinal 
epithelial barrier through M cells and reach the lamina propria underneath where they get 
phagocytosed by macrophages. EHEC’s Stx production occurs in the intestine and continues 
within the macrophages as the bacteria survive their immune response. Stx production within 
the macrophages leads to apoptosis of macrophages, and thereby releases the Stx toxin which 
can cross the downstream blood vessels to reach the kidneys, intestine, and brain [13] of the 
human body.  
2.3 Impact of diseases related to E. coli O157:H7 infections 
Diseases caused by infection with E. coli O157:H7 range from vomiting, stomach cramps, bloody 
diarrhea to haemolytic-uraemic syndrome (HUS) or haemorrhagic colitis (HC). HUS was first 
described in 1955 and consists of an acute febrile illness followed by acute renal failure and 
intravascular haemolysis [58]. HC is characterized by sudden severe abdominal colic and grossly 
bloody diarrhea and was first described by Riley et al. 1983.  
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Currently for EHEC infections there is no treatment available [21]. It was found that the use of 
conventional antibiotics makes Shiga toxin-mediated cytotoxicity worse. In an epidemiology 
study conducted by the Centers for Disease Control and Prevention, patients treated with 
antibiotics for EHEC enteritis had a higher risk of developing HUS [56]. Additional studies support 
the contraindication of antibiotics in EHEC infection. Antibiotics promote Shiga toxin production 
by enhancing the replication and expression of stx genes that are encoded within a 
chromosomally integrated lambdoid prophage genome [65]. A promising way to treat EHEC 
infections is the usage of probiotics, such as E. coli Nissle 1917. To change the composition of 
the normal intestinal microbiota from a potentially harmful composition towards a microbiota 
that would be beneficial for the host has always been the original idea with probiotics [2], [32]. 
2.4 General background of probiotic Escherichia coli Nissle 1917 
E. coli Nissle 1917 belongs to the non-pathogenic E. coli strains. It is one of the best analyzed E. 
coli strains so far and is used in the medical field to treat several intestinal or colon related 
diseases.   
Several characteristics make E. coli Nissle 1917 such a candidate as a probiotic. It has been 
shown to produce no toxins like heat-labile or heat-stabile toxins and no Shiga-like toxins, as 
EDL933 does. E. coli Nissle 1917 is non-invasive and doesn’t form hemolysins, doesn’t possess 
any stx genes [26]. It expresses no CFA I or CFA II fimbriae and has no P-, M-, or S- fimbriae [26]. 
Focusing on its intestinal colonization ability, E. coli Nissle 1917 is generally able to colonize the 
human gut as well as the mouse intestine [49].  It is able to easily colonize newborns if 
administered within the first few days after birth, when the colonization resistance is not yet 
well established. This has been shown in a study in a neonatal unit of a hospital in Hagen as well 
as in a children’s hospital in Prague [11].  Here they postulate that E. coli Nissle 1917’s 
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colonization of premature infants stimulates significantly nonspecific natural immunity. To 
successfully colonize the intestine of adults, it has been shown that this is easily achieved after 
gut decontamination and/or lavage [32].  
2.5 The mammalian large intestine 
The large intestine is the terminal part of the digestive system after the stomach and small 
intestine. The small intestine absorbs most of the nutrients. The large intestine consists of three 
main sections: the cecum, the colon and the rectum [61]. Its main function is to reabsorb water 
and inorganic salts [63]. The epithelial surface of the large intestine is unlike the small intestine, 
rather smooth without intestinal villi and consists of goblet cells and enterocytes [61]. The 
mucus layer overlies the epithelial surface and is relatively thick. It consists of mucin, a 2-MDa-
gelforming glycoprotein and a large number of smaller glycoproteins, proteins, glycolipids, lipids 
and sugars [3], [50], [60]. The mucus layer is in a dynamic state meaning it is constantly being 
synthesized and secreted by the mucin-secreting goblet cells and is degraded to a larger extent 
by the indigenous intestinal microbes [63], [41]. Degraded mucus components are shed into the 
intestinal lumen, forming a part of the luminal content that is excreted in the feces [41]. 
To digest and uptake all necessary nutrients the intestine is supported by a huge variety of 
bacteria colonizing the inner surface and interacting with each other. This is a symbiosis 
between host intestine and bacteria, since food is presented to bacteria of the digestive system 
and they in return provide breakdown products of molecules which cannot be broken down by 
the intestinal enzymes alone. There are about 500 major bacterial strains in the intestine, which 
interact with each other symbiotically [15]. The microbiota in the intestine of humans and 
animals consists of a variety of different bacteria including obligate anaerobes such as 
Bacteriodes, Bifidobacterium, Clostridium, Eubacterium, Fusobacterium, Lactobacillus, 
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Peptococcus, Peptostreptococcus and Veillonella [35, 54]. The obligate anaerobes in the 
mammalian intestine make up greater than 99.9% of the cultivable bacteria [44]. The 
predominant facultative anaerobe in the gastrointestinal tract is Escherichia coli [15]. 
According to Freter et al. 1983 there are four microhabitats within each section of the intestine 
[52]. There is the surface of the epithelial cells, the deep mucus layer of the crypts in the ileum, 
cecum and colon, the mucus layer that covers the epithelial cells throughout the intestinal tract 
in the cecum and colon of the mammalian intestine and finally the lumen [52]. Commensal E. 
coli strains colonize the mucus layer covering the epithelial cells [43], whereas especially 
pathogenic E. coli strains colonize the surface of the epithelial cells via attachment to specific 
receptors [9, 31].  
2.6 Mouse models used in colonization studies 
The animal model of a conventional laboratory mouse would be ideal to study intestinal 
colonization of E. coli, since its microbiota and biofilm interactions are congruent with those of a 
conventional human patient. The major problem with this model is to introduce and colonize an 
invader strain in an established microbiota, meaning to overcome colonization resistance [63]. 
To prevent this difficulty there are other animal models, such as the germfree animal which 
doesn’t contain an established microbiota, since it has never been exposed to a natural germ-
containing environment. This animal model is not only very expensive it also doesn’t reflect 
natural intestinal colonization [63]. The streptomycin-treated mouse model was established in 
1954 by Bohnhoff et al. [7]. The advantage of this animal model is that the intestine can be 
cleared of native facultative anaerobe bacteria [23], such as facultative anaerobic enterobacocci, 
streptococci, lactobacilli, anaerobic lactobacilli and bifidobacteria purely by adding the antibiotic 
streptomycin in the drinking water (5g/L). However, besides changes in the concentration of 
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volatile fatty acids and a decrease of pH (6.42 to 6.73), the numbers of strict anaerobes and 
populations of the genera Bacteriodes and Eubacterium remain unchanged [23]. The advantages 
of this animal model are its relatively low cost and a relatively simple colonization procedure by 
providing streptomycin in drinking water and feeding streptomycin resistant bacteria to the 
mice. The streptomycin-treated mouse model is used during this study. 
2.7 Nutritional aspects of colonizing the mouse large intestine 
The dominant glycoprotein of the intestinal mucus is mucin which consists of about 80% 
polysaccharide and 20% protein [1]. The five major sugars in mucin are N-acetylgalactosamine, 
N-acetylglucosamine, N-acetylneuraminic acid, L-fucose and D-galactose [1]. The mucus layer in 
the mouse intestine also contains smaller proteins, glycoproteins, lipids and glycolipids, and 
sugars like arabinose, mannose and ribose [1], [50]. 
As about 500 different cultivable bacteria provide a very diverse microbiota, each organism is 
best served to cultivate a specific ecological niche in order to be maintained in the intestine. 
Those ecological niches can be defined by nutrient availability according to Freter et al. 1983 
[52], such that the population size of an individual species in the large intestine depends on the 
available concentration of its preferred nutrient. The population of E. coli in the intestine is 
relatively small, despite its rapid growth rate, which indicates that the concentration of its 
preferred monosaccharide(s) is low. To survive in the intestine without being physically attached 
to the host intestinal wall, a bacterial strain would have to out-compete all other organisms for a 
particular nutrient or nutrient mixture, since failure to do so would lead to displacement from 
the host. To be able to make predictions about nutritional competition between simultaneously 
colonizing E. coli strains in the mouse large intestine, it is necessary to understand which 
pathways are utilized by each strain while growing in the intestine.  
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2.8 The Emden-Meyerhof Parnas pathway (glycolysis)  
A major metabolic pathway for glucose utilization is the Entner-Doudoroff pathway, which is 
present in bacteria but not eukaryotes and is needed to break down gluconate, a sugar also 
present in the mucus layer of the intestine [59]. The Pentose-Phosphate pathway is needed to 
produce pentose phosphates and the Emden-Meyerhof Parnas pathway provides  glucose for 
glycolysis into pyruvate.  
Glycolysis degrades one molecule of glucose (six-carbon molecule) in a series of enzyme-
dependent reactions and yield two molecules of pyruvate (three-carbon molecule) [55]. During 
several enzyme-catalysed steps, energy is released and conserved in the form of ATP and NADH. 
Each molecule of pyruvate can then be decarboxylized to yield acetyl-CoA which enters the TCA 
cycle and serves to conserve more energy [55].  
The breakdown of glucose into two molecules of pyruvate occurs during 10 reaction steps [36]. 
Glucose is first phosphorylated at the hydroxyl group of C-6 (by hexokinase) to D-glucose 6-
phosphate. This is further converted into D-fructose 6-phosphate (by phosphohexose 
isomerase). D-fructose 6-phosphate is phosphorylated at its C-1 leading to D-fructose 1,6-
bisphosphate (by phosphofructokinase-1). ATP is for both phosphorylation reactions the 
phosphoryl group donor. D-fructose 1,6-bisphosphate is further split into dihydroxyacetone 
phosphate (DHAP) and into glyceraldehyde 3-phosphate (by aldolase). DHAP and glycerol 3-
phosphate are isomerized by triose phosphate isomerase. During the next reaction step, two 
molecules of glyceraldehyde 3-phosphate are phosphorylated by inorganic phosphate to two 
molecules of 1,3-bisphosphoglycerate (by glyceraldehyde 3-phosphate dehydrogenase), while 
two molecules of NADH are created. Converting two molecules of 1,3-bisphosphoglycerate by 
substrate-level phosphorylation into two molecules of 3-phosphoglycerate (by 
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phosphoglycerate kinase) energy is released in form of two molecules of ATP. The enzyme 
phosphoglycerate mutase converts two molecules of 3-phosphoglycerate each into 2-
phosphoglycerate. Dehydration of two molecules of 2-phosphoglycerate (by enolase) leads to 
two molecules of phosphoenolpyruvate (PEP). Finally, two molecules of PEP are converted into 
two molecules of pyruvate via substrate-level phosphorylation (by pyruvate) kinase, releasing 
energy in the form of two molecules of ATP [46]. The net yield of energy conversion is two 
molecules of ATP and two molecules of NADH per molecule of glucose. To assure a steady 
supply of ATP, glycolysis is tightly regulated in coordination with other energy-yielding pathways 
[55]. 
2.9 The tricarboxylic acid (TCA) cycle  
The TCA cycle can be used both under aerobic and anaerobic conditions. It is the second major 
stage of respiration which enzymatically further oxidizes the pyruvate produced by glycolysis 
into H2O and CO2 [64]. The energy released during these oxidation reactions is conserved in the 
reduced coenzymes and electron carriers NADH and FADH2. They themselves undergo oxidation 
during the third stage of respiration, and transfer their electrons to O2, producing ATP by the 
electron flow [46].  
The TCA cycle is comprised of eight steps [39]. Pyruvate, the product of glycolysis is converted 
into acetyl-CoA by pyruvate dehydrogenase, and the acetyl-CoA molecule enters the TCA cycle. 
First citrate is formed by condensation of the incoming acetyl-CoA with oxaloacetate, catalyzed 
by citrate synthase. Second isocitrate is formed via cis-aconitate by adding a H2O molecule 
catalyzed by aconitase. Third oxidative decarboxylation of isocitrate forms α-ketoglutarate and 
one molecule of CO2. This reaction is catalyzed by isocitrate dehydrogenase and also forms a 
molecule NADH by electron transfer. Fourth another oxidative decarboxylation reaction 
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produces succinyl-CoA and CO2. The reaction is catalyzed by α-ketoglutarate dehydrogenase and 
transfers an electron to NAD+, leading to NADH. Fifth succinyl-CoA is converted into succinate by 
succinyl-CoA synthetase and thereby produces GTP. Sixth succinate is oxidized to fumarate 
catalyzed by succinate dehydrogenase. This reaction also produces FADH2. In a seventh step 
fumarate is hydrated to malate by fumarase. And in the last eighth step malate dehydrogenase 
catalyzes the oxidation of malate to oxaloacetate and thereby producing NADH2 [46].  
This pathway is cyclic which means that the intermediates of the cycle are not used up. For one 
molecule of oxaloacetate consumed in the TCA cycle, one is produced. The energy gain per 
acetyl-CoA oxidized by the TCA cycle are three molecules of NADH, one molecule of FADH2 and 
one molecule of nucleoside triphosphate (ATP or GTP) [64].  
The TCA cycle is not only dependent on entering molecules of acetyl-CoA. Any four or five-
carbon intermediate of the TCA cycle can be oxidized further. These intermediates can be 
products of amino acid breakdowns [36].  
2.10 Gluconeogenesis  
Gluconeogenesis (“new formation of sugar”) is needed as a method for synthesizing glucose 
from non-carbohydrate precursors by E. coli when glucose is depleted. Gluconeogenesis in E. 
coli  (see figure 1) starts from simple organic compounds of two or three carbons, such as 
lactate, acetate and propionate, in their environment or growth medium [46] and it is needed to 
convert pyruvate and related three- and four-carbon compounds (including TCA cycle 
intermediates) to glucose [46]. Seven of the reaction steps in gluconeogenesis are catalyzed by 
the same enzymes as in glycolysis (see glycolysis). Different enzymes are used to reverse three 
irreversible reaction steps of glycolysis. These reaction steps are first of all the conversion of 
pyruvate to PEP via oxaloacetate (catalyzed by pyruvate carboxylase and PEP carboxykinase). 
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Second it is the dephosphorylation of fructose 1,6-bisphosphate by FBPase-1. And third it is the 
dephosphorylation of glucose 6-phosphate by glucose 6-phosphatase [36]. Gluconeogenesis is 
energetically expensive as the formation of one molecule of glucose from two molecules of 
pyruvate requires two molecules of NADH and six high-energy phosphate groups coming from 
four molecules of ATP and two molecules of GTP [55]. Gluconeogenesis and glycolysis have to be 
reciprocally regulated to prevent wasteful operation of both pathways at the same time. Some 
or all of the carbon atoms of most amino acids derived from proteins are ultimately catabolized 
to pyruvate or to intermediates of the TCA cycle. Such amino acids can therefore undergo net 
conversion to glucose and are said to be glucogenic [46]. 
2.11 Glyoxylate shunt  
Bacteria like E. coli contain the full repertoire of enzymes needed for the glyoxylate cycle as well 
as those for the TCA cycle in the cytosol. This way they are able to grow on acetate as their sole 
carbon and energy source [36]. Organisms that lack the glyoxylate shunt cannot synthesize 
glucose from acetate or fatty acids that give rise to acetyl-CoA. In the glyoxylate cycle , acetyl-
CoA is condensed together with oxaloacetate to form citrate. Citrate is further converted into 
isocitrate, just like in the TCA cycle. Starting from isocitrate both pathway differ. In the 
glyoxylate cycle isocitrate is cleaved into succinate and glyoxylate by the enzyme isocitrate 
dehydrogenase. Glyoxylate together with an additional acetyl-CoA forms malate. This reaction is 
catalyzed by the enzyme called malate synthase. Malate is finally converted into oxaloacetate, 
which can either condense with another acetyl-CoA and start another turn of the cycle or it can 
undergo gluconeogenesis and generate glucose. Each turn of the glyoxylate cycle converts two 
molecules of acetyl-CoA into one molecule of succinate and one molecule of malate. Succinate 
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can also undergo another turn of the TCA cycle or it can be converted into fumarate, then 
malate, then oxaloacetate and follow the steps of gluconeogenesis to PEP and glucose [46].  
Since the carbon atoms of acetate molecules are converted in 8 steps to oxaloacetate in the TCA 
cycle, the TCA cycle itself should be able to generate PEP for gluconeogenesis from acetate. But 
looking at the stoichiometry of the TCA cycle, there is no net conversion of acetate to 
oxaloacetate. For every two carbons which enter the cycle as acetyl-CoA, two carbons leave as 
CO2 which makes it impossible to generate PEP out of it. Looking at the glyoxylate cycle, the two 
steps of decarboxylation of the TCA cycle are bypassed and with this the net formation of 
succinate, oxaloactetate and other cycle intermediates from acetyl-CoA becomes possible [46]. 
As there are many common intermediates being shared between these pathways, they are 
coordinately regulated. This is accomplished by a covalent but reversible modification of the 
enzyme isocitrate dehydrogenase. The level of isocitrate dehydrogenase is dependent on its 
reversible phosphorylation and regulates the partitioning of isocitrate between the TCA cycle 
and the glyoxylate cycle [39]. 
2.12 Gene knockout mutants used in colonization experiments 
Since the effect of gluconeogenesis during colonization of the mouse large intestine is analyzed 
and the effect of the glyoxylate shunt is discussed during this study, knockout mutants of the 
genes which are necessary to utilize both metabolic pathways are generated. 
Two required genes involved in gluconeogenesis are pckA and ppsA. The pckA gene encodes for 
phosphoenolpyruvate (PEP) carboxykinase (EC 4.1.1.49) which is an enzyme catalyzing the first 
step of gluconeogenesis in E. coli [38]. It phosphorylates and decarboxylates the TCA cycle four-
carbon intermediate oxaloacetic acid to PEP [53]. PEP carboxykinase is activated by calcium [19] 
and the pckA gene’s expression is regulated by cyclic AMP [20]. 
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The ppsA gene encodes for PEP synthetase (EC 2.7.9.2), an enzyme which catalyzes the 
phosphorylation of pyruvate to PEP, being activated by a Pi-dependent pyrophosphorylation 
(ATP) and inactivated by an ADP-dependent phosphorylation on a regulatory threonine [8]. 
During growth on three-carbon substrates that require the gluconeogenesis pathway (such as 
lactate or pyruvate), phosphoenolpyruvate (PEP) synthetase provides the ability to generate 
phosphoenolpyruvate, which is required for the synthesis of precursor metabolites for cellular 
carbon compounds [10]. 
A ΔpckA ΔppsA double mutant does not grow on acetate [48] or succinate [20] as the sole 
source of carbon, but is able to grow on carbon sources that enter central carbon metabolism 
“above” PEP such as glycerol. 
A required gene involved in the glyoxylate shunt is the gene aceA. The aceA gene encodes for 
the enzyme isocitrate lyase (EC 4.1.3.1) which catalyzes the cleavage of isocitrate, forming 
succinate and glyoxylate, a key step of the glyoxylate shunt. It is activated by phosphorylation on 
histidine and is inhibited by PEP, 3-phosphoglycerate and succinate [24]. The second reaction of 
the glyoxylate shunt is catalyzed by an enzyme called malate synthase and catalyses the 
condensation of glyoxylate with a second molecule of acetyl-CoA, forming malate [34]. The 
malate is then oxidized to oxaloacetate, which can either start another turn of the cycle or can 
be converted to PEP by PEP carboxykinase and undergo gluconeogenesis to form glucose [46]. 
The glyoxylate shunt bypasses two CO2-evolving steps of the TCA cycle, allowing the net 
accumulation of carbon from acetyl-CoA [34]. To be able to grow on substrates such as acetate 
or fatty acids, E. coli needs operation of the glyoxylate shunt [30]. This indicates that an E. coli 




In Figure 2 the major metabolic pathways of E. coli are shown. 
 
Figure 2: The Embden-Meyerhof-Parnas pathway, gluconeogenic pathway, and TCA cycle. 
Arrows indicate the physiological directions of the reactions. Genes encoding the enzymes for 
each reaction are listed beside each reaction [41]. The Embden-Meyerhof-Parnas pathway starts 
at the six carbon sugar glucose and breaks it down to two molecules of pyruvate (C-3). Pyruvate 
further enters the TCA cycle and energy in form of ATP, GTP, NADH is released as well as CO2 as 
a one carbon molecule. The reverse pathway which is important when there is a depletion of 
sugar carbon sources in the environment, is the gluconeogenesis pathway. It allows the 
organism to regenerate glucose out of gluconeogenic substrates such as TCA cycle 
intermediates, amino acids and other molecules which enter the TCA cycle. Glycolysis yields two 
high energy phosphate bonds of ATP, gluconeogenesis expends six high energy phosphate bonds 
of ATP. A futile cycle consisting of both pathways would waste four high energy phosphate 
bonds of ATP. To prevent this waste glycolysis and gluconeogenesis are reciprocally regulated.  
To be able to metabolize acetate or fatty acids, the organism has to be able to use the glyoxylate 
shunt. Both substrates can enter the TCA cycle at acetyl-CoA (C2) and be modified to isocitrate. 
Starting from isocitrate the TCA cycle is not used anymore, since two molecules of CO2 would be 
lost, each during the step leading to alpha-ketoglutarate and the step leading to succinyl-CoA. 
Since two carbons would be lost, another round of the TCA cycle would be impossible. The only 
possibilities are to use the glyoxylate shunt avoiding the loss of two molecules of CO2 as well as 
using so called anapleurotic reactions such as from PEP to oxaloacetate (C4) which provide two 




3.1 Agarose gel electrophoresis 
This technique is used to separate DNA fragments based on their size and charge. The 
composition of the gel is 1% [m/v] of multi-purpose agarose (Fisher Scientific, Fair Lawn, NJ) in 
100 ml TAE buffer (40 mM Tris-acetate; 1 mM EDTA, Inc., Boulder, CO) with 0.2-0.4 µg/ml  of 
ethidium bromide (Sigma Chemical Co., St. Louis, MO). As the DNA standard marker, a 1 kb DNA 
Ladder (Promega Corporation, Madison, WI) is chosen. 
3.2 Agarose gel photography 
To visualize DNA bands, a Fotodyne ultra-violet transilluminator (Fotodyne, Inc., New Berlin, WI) 
is used and a Kodak DC12 Zoom Digital Camera (Eastman Kodak Company, Rochester, NY) 
photographs the DNA bands in the gel. Analysis of the digital photographs is done with the help 
of the Kodak Digital Science 1D software (version 3.0.2; Eastman Kodak Company, Rochester, 
NY). 
3.3 Bacterial strains and plasmids 
The bacterial strains as well as the plasmids used in this study are listed in Table 2. E. coli Nissle 
1917 is a human commensal strain. It has been used as a probiotic agent since the early 1920s. 
Originally the strain was isolated during World War I from a soldier who escaped a severe 
outbreak of diarrhea affecting his regiment [57]. Since the 1920s E. coli Nissle 1917 has been 
marketed as a probiotic remedy against intestinal disorders in several European countries. E. coli 
EDL933 is an O157:H7 strain isolated from an outbreak caused by contaminated beef in 1982 
[51]. It is known to be a noninvasive enteric shiga toxin producing pathogen causing 
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gastrointestinal illnesses including hemolytic uremic syndrome (HUS) and hemorrhagic colitis 
(HC) in humans [29, 51] and is ingested by eating undercooked food. 
3.4 Biolog 
The Biolog is a phenotype microarray based on metabolic capabilities. For purposes of this study 
GN2 MicroPlateTM (Gram negative carbon nutrition) plates are chosen. 95 different nutrients and 
biochemicals are dried into the wells of each plate (see Table 1).  
Table 1: 96 different nutrients of the GN2 MicroPlate TM [6]. All nutrients and biochemicals are 
dried into the 96 wells of the plate. The redox dye tetrazolyum violet is used to indicate the 
utilization of the carbon source. The result is an individual “metabolic fingerprint” of the 
bacterial strain tested [6]. 
 
The Biolog GN2 MicroPlates are designed to test the ability of gram-negative bacteria to utilize 
or oxidize compounds from the 96 different carbon sources. This provides a metabolic 
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fingerprint to each individual strain, which can be compared to other strains to screen for 
similarities and especially differences in metabolizing these nutrients [6]. Utilizing Biolog GN2 
MicroPlates, cells are grown over night in 1x M9 medium containing 0.4 % glycerol and 0.2 M 
NaCl. Cultures are washed twice in 1x M9 medium containing 0.2 M NaCl without any carbon 
source and are then diluted to an OD600 of 0.06 in 5 ml of 1x M9.  The culture is diluted 10 fold 
before 100 µl/well are delivered into a microtiter 96-well GN2 MicroPlate. The plates are placed 
into the OmniLog for 48 h at 37 °C. During incubation the cells oxidize the provided carbon 
sources and simultaneously reduce a tetrazolium violet dye which is measured at 15 min 
intervals and plotted vs. time using the Biolog’s MicroLog computer software. The final outcome 
is a kinetic curve for each well. The area under the curve is serving as a measurement of 
oxidation of each carbon source provided in every well. To compare the metabolic fingerprint of 
two strains (one represented in red the other one in green), the kinetic curves are laid on top of 
each other, showing overlapping areas (yellow) where the oxidation of carbon sources is the 
same for both strains or one colored areas indicating utilization of the provided carbon source of 
only one of the strains [6]. 
3.5 Construction and characterization of Escherichia coli mutants 
Gene deletion mutants are constructed by allelic exchange mutagenesis originally described by 




Table 2: Bacterial strains and plasmids 





E. coli Nissle 1917 Str
r Spontaneous streptomycin -resistant mutant of 
Nissle 1917 
[4] 
E. coli Nissle 1917 Str
r
 Nal
r Spontaneous nalidixic acid-resistant mutant of 
Nissle 1917 Str
r [4] 
E. coli Nissle Str
r
 ΔpckA ΔppsA :: cat 
pckA ppsA double deletion mutant of Nissle 
1917 Str
r
, carrying a chloramphenicol resistance 
cassette in the ppsA deletion, unable to 
metabolize gluconeogenic substrates 
This study 
E. coli Nissle Str
r
 ΔaceA:: cat 
Replacement of aceA gene by a 
chloramphenicol resistance cassette, unable to 
metabolize fatty acids and actetate 
This study 
E. coli EDL933 Str
r Spontaneous streptomycin-resistant mutant of 
EDL933 
[42] 










E. coli EDL933 Str
r
 ΔpckA ΔppsA:: cat 
pckA ppsA double deletion mutant of EDL933 
Str
r
, carrying a chloramphenicol resistance 
cassette in the ppsA deletion, unable to 
metabolize gluconeogenic substrates 
[42] 
pKD3 
Template plasmid, contains chloramphenicol 




Temperature-sensitive plasmid, contains L-




Temperature-sensitive plasmid, contains FLP 






, streptomycin resistance; cat, chloramphenicol resistance; Rif
r
, rifampin resistance 
 
The complete sequence of E. coli Nissle 1917 is not available. Therefore, for constructing the E. 
coli Nissle 1917 mutants, the primers are designed referring to the complete genome of E. coli 
CFT073 (see Table 3), a strain closely related to E. coli Nissle 1917. Both forward and reverse 
primers are designed with flanking FLP Recombinase Site (FRT). The gene knockouts take place 
via substitution by a cassette construct containing the FRT sites, the homologous regions of the 
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gene to knock out, and a chloramphenicol sequence as a selection marker. The chloramphenicol 
cassette is PCR amplified using pKD3 as template.  
Table 3: PCR primers used for deletion and confirmation of the deletion. Upper case letters of 
the primer sequences are E. coli gene specific, and bold upper case letters are specific to plasmid 
pKD3. 
PCR primer  Primer sequences in  5’→3’ direction 
E. coli Nissle pckA forward primer 5'-GTTAATTATCGCATCCGGGCA-3' 
E. coli Nissle pckA reverse primer 5'-GTTGTCGATAAACAGTTTCGCCAG-3' 
E. coli Nissle pckA P1 primer 
5'-AGACTTTACTATTCAGGCAATACATATTGGCTA 
AGGAGCAGTGGTGTAGGCTGGAGCTGCTTCG-3' 
E. coli Nissle pckA P2primer 
5'-GCGGGTATCTTTAATCGAGATACGTTTGCC 
AGTGCCGTTCCAGCATATGAATATCCTCCTTAG-3' 
E. coli Nissle ppsA forward primer 5'-CCTGTGTGGTTGCAATGTCCG-3' 
E. coli Nissle ppsA reverse primer 5'-TTGTTCTTCCCGTGATGCAGAC-3' 
E. coli Nissle ppsA forward2 primer 5'-AACCACCGCTTTCGCCTGA-3' 
E. coli Nissle ppsA reverse2 primer 5'-CAGAAGATATGCCGGACGCTTCT-3' 
Wanner primer towards P1 (start 
inside Cam-cassette) 5'-CAACAGTACTGCGATGAGTGGCAG-3' 
Wanner primer towards P2 (start 
inside Cam-cassette) 5'-GCGAAGTGATCTTCCGTCACAGGT-3' 
E. coli Nissle, EDL aceA forward primer 5'-ACGCTTGATGGAACAGATCACC-3' 
E. coli Nissle, EDL aceA reverse primer 5'-CGAAGTAACCTGTACCCACTTCC-3' 
E. coli Nissle, EDL aceA P1 primer 
5'-TGAAGAATTACAGAAAGAGTGGACTCAACC 
GCGTTGGGAAGGCATATGAATATCCTCCTTAGT-3' 






Cells to be transformed carry the plasmid pKD46 which is a necessary tool as it is temperature 
sensitive and contains an ampicillin resistance gene as well as a λ-red recombinase needed for 
homologous recombination. The cells are grown in 10 ml super optimal broth (SOB) medium 
[12] at 30 °C to an OD600 of 0.6 and are then made electrocompetent by washing three times 
with ice-cold 10 % glycerol and concentrating the cell concentration 100-fold. 50 µl of the cells 
mixed with 2 µl of the PCR amplicons are electroporated using the instructions of the Bio-Rad 
gene pulser at 2.5 V and immediately recovered by adding 950 µl of SOB medium and shaking it 
at 37 °C with 200 rpm for at least 2 h. After 2 h homologous recombination should have taken 
place and 300 µl of the culture suspension is plated on LB plates containing chloramphenicol (30 
µg/ml) to select chloramphenicol resistant transformants. After 24 h remaining at room 
temperature, the remainder is plated as well. After primary selection at 37 °C, mutants are 
colony-purified and additionally tested for ampicillin sensitivity to make sure the mutants have 
lost the pKD46 plasmid. Since pKD46 is temperature-sensitive, it gets lost by growing cells at 
43°C. Using this allelic replacement method the genes aceA, pckA or ppsA are knocked out in E. 
coli Nissle 1917.  
Since genes pckA and ppsA have to be knocked out in the same organism to asure that its ability 
to use gluconeogenesis is lost completely, the protocol of constructing a second gene deletion is 
followed. To be able to use the same chloramphenicol cassette with different homologous 
regions of the corresponding gene, the already inserted chloramphenicol cassette is removed by 
electroporation with pCP20. This plasmid contains a FLP recombinase to remove the sequence 
between both FRT sites.  The procedure is repeated as already described except for growing and 
recovering the cells in LB broth instead of SOB medium and for plating transformants on LB 
plates containing ampicillin (100 µg/ml). To lose pCP20 again, the cell culture is grown in LB 
broth at 43 °C for a maximum of 5 h and plated on LB plates at 37 °C. The final selection is done 
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by toothpicking on LB, chloramphenicol and ampicillin plates to select for AmpS and CamS 
mutants. These mutants have lost the chloramphenicol cassette and are prepared to generate 
the second mutation. To knockout the second gene, electroporation with the appropriate PCR 
amplicon is done as previously described for the first gene knockout. Each mutant is verified via 
PCR and DNA sequencing. 
3.6 DNA Sequencing 
Sequencing is done at the University of Rhode Island Genomic and Sequencing Center, 
University of Rhode Island, Kingston, using the Appled Biosystems 3130xl Genetic Analyzer 
(Applied Biosystems, Foster City CA). 
3.7 Growth media and conditions 
Bacterial cultures are usually grown in Luria broth (LB) (by Difco Laboratories, Detroit, MI). 
Routine bacterial growth on plates is on LB agar (Lennox formulation; Difco Laboratories, 
Detroit, MI) containing appropriate antibiotics. LB agar consists of Luria broth containing 12g of 
Bacto Agar (Difco) per liter ddH2O. For Transformation experiments liquid cultures are grown 
and recovered in super optimal broth (SOB) medium according to the description of Datsenko 
and Wanner [12]. It consists of 2% [m/v] BactoTM-tryptone (Difco Laboratories, Detroit, MI), 0.5% 
[m/v] yeast extract (Difco Laboratories, Detroit, MI), 10 mM NaCl (Sigma Chemical Co., St. 
Louis,MO), 2.5 mM KCl (Sigma Chemical Co., St. Louis,MO), 10 mM MgCl2 6 H2O (Sigma Chemical 
Co., St. Louis, MO), and 10 mM MgSO4 7 H2O (Sigma Chemical Co., St. Louis, MO). 
M9 minimal broth medium as described by Miller [40] is used to determine bacterial growth and 
utilization of a manually added carbon source. M9 minimal medium consists of 90% ddH2O, 10% 
10x M9 salts, 1 mM MgSO4 solution and 100 µM CaCl2 solution. The needed 10x M9 salt solution 
is made of 60 g Na2HPO4, 30 g KH2PO4, 10 g NH4Cl and 5 g NaCl dissolved in ddH2O up to 1 liter. 
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The carbon sources are added to the M9 minimal broth medium at concentrations of glycerol 
(0.4% [v/v]), acetate (0.2% [m/v]), and succinate (0.2% [m/v]). These carbon sources were all 
purchased from Sigma Chemical Co., St. Louis, MO. The M9 medium is used at its original 0.1 M 
NaCl concentration as well as at a total concentration of 0.2 M NaCl, since this is the molarity 
found in the mammalian intestine and therefore closely relates to the in vivo circumstances in 
natural colonization environments. For testing the ability of E. coli strains to utilize succinate or 
acetate, the overnight cultures grown in LB are washed twice with M9 minimal medium without 
any carbon source. 100µl of the washed culture are transferred into 10 ml of M9 minimal 
medium containing glycerol (0.4% [v/v]) as the only carbon source. The bacterial cultures are 
incubated overnight at 37°C in 125 ml tissue culture bottles placed in a shaking bath (200 rpm). 
The following day 100µl of the grown culture are transferred into freshly made M9 minimal 
medium containing the carbon source of interest. Growth is monitored spectroscopically (OD600) 
using a Pharmacia Biotech Ultrospec 2000 UV/Visible Spectrometer. 
For colonization experiments E. coli strains are plated and selected on MacConkey agar plates 
(Difco Laboratories, Detroit, MI) containing appropriate antibiotics. The plates are prepared as 
described in the package instructions. Bacteria plated on MacConkey agar are incubated 
overnight at 37°C unless otherwise indicated. All bacterial culture dilutions for colonization 
experiments are made in 1% [m/v] BactoTM-tryptone (Fisher Scientific, Fair Lawn, NJ). 
The antibiotics streptomycin sulfate, chloramphenicol, and nalidixic acid are purchased from 
Sigma-Aldrich (St. Louis, MO). Rifampin is purchased from Fisher Scientific (Pittsburgh, PA). Final 
concentrations of these antibiotics in media unless otherwise indicated are streptomycin sulfate 
(100 μg/ml), nalidixic acid (50 μg/ml), chloramphenicol (30 μg/ml) and rifampin (50 μg/ml).  
25 
 
3.8 Growth of bacterial cultures 
To determine bacterial growth the cell density can be spectrometrically measured using a 
Pharmacia Biotech Ultrospec 2000 UV/visible spectrometer, since the light beam which passes 
through the cuvette is scattered depending on the cell density. The optical density (OD) is 
proportional to the cell density. The OD measurement occurs at a wavelength of 600 nm. The 
accurate detection range lies between the OD of 0.1 and 0.6 which requires appropriate culture 
dilutions. A growth curve can be made by plotting the OD600 value versus time.  
3.9 Isolation, purification and quantification of DNA 
Overnight cultures are grown in LB broth at 37 °C. To isolate genomic DNA the Promega Wizard 
Genomic DNA isolation kit (Catalog number A1120 Promega Corporation, Madison, WI) is used. 
Storage of isolated genomic DNA is at -20°C. Plasmid DNA is isolated using Eppendorf’s Fast 
Plasmid Mini kit (Catalog number 955150601 Brinkmann Instruments, Inc., Westbury, NY). 
Overnight cultures for this procedure are grown in LB broth at 30°C and the plasmid DNA is 
stored at -20°C.  
PCR amplified DNA products are concentrated via ethanol precipitation by adding one tenth of 
its volume of 3 M sodium acetate pH 5.4 (Sigma) and adding 800 µl of 95 % ethanol (Quantum 
Chemical Co., Tuscula, IL). DNA precipitation is done for 24 h at 4 °C. Afterwards the DNA is 
pelleted in a microcentrifuge for 10 minutes at 13,000 x g. The supernatant is removed, the 
pellet washed by centrifugation with 700 µl of 70 % ethanol and air dried for 10 min. The last 
step is rehydration in nuclease free water (Molecular Biology Grade PCR water, Fisher Scientific, 
Pittsburg, PA) for several hours. This PCR product is also stored at -20°C. 
For sequencing purposes PCR amplified genomic DNA is purified using the instructions by the 
QIAGEN QIA quick PCR purification kit (Catalog number 28104). 
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3.10 Streptomycin-treated mouse model used for colonization experiments 
The streptomycin-treated mouse model is used to investigate the in vivo carbon nutrition of E. 
coli strains and to study the competition in the intestine between streptomycin-resistant E. coli 
strains. Since the numbers of an E. coli strain in the mouse large intestine is reflected by their 
numbers in mouse feces [27], fecal counts are used to judge the relative colonizing abilities of E. 
coli mutants and wild type strains. The streptomycin-treated mouse model has been extensively 
used by Dr. Cohen’s laboratory group [9, 14, 17, 18, 43, 49, 60, 62] and is well established. 
Treatment of mice with streptomycin during the whole time of colonization is needed to 
overcome colonization resistance on one hand by the loss of facultative anaerobes from the 
microbiota and on the other hand by the observed decrease in the concentrations of short-chain 
fatty acids and hydrogen sulfide [23]. The antibiotic streptomycin is a protein synthesis inhibitor 
which prevents binding of the tRNAfMet to the bacterial ribosome and therefore leads to codon 
misreading, protein synthesis inhibition and finally to cell death [66]. E. coli Nissle 1917 StrR, and 
E. coli EDL933 StrR contain the same point mutation in rpsL which makes them resistant to 
greater than 2 mg/ml of streptomycin sulfate [16]. Some of the introduced E. coli strains used in 
the colonization experiments are, in addition to being streptomycin resistant, also resistant to 
either chloramphenicol, nalidixic acid, or rifampin, genetic markers that have no effect on their 
colonization abilities [9, 42, 43]. 
For colonization experiments mice in the animal facilities in Morrill Hall are given streptomycin 
sulfate in their drinking water (5 g/liter) over the entire course of these experiments, which 
selectively removes facultative anaerobic E. coli, enterococci, streptococci, lactobacilli, and 
anaerobic lactobacilli and bifidobacteria [23]. It is important to note that the overall populations 
of anaerobes, including Bacteroides and Eubacterium, are unchanged in the cecal contents 
following streptomycin treatment [23].  
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The specific procedure of colonization experiments in streptomycin-treated mice has been 
already described [37, 59, 60]. Briefly, three male CD-1 mice (5 to 8 weeks old) are given 
drinking water containing streptomycin sulfate (5 g/liter) for 24 h. Following this treatment the 
mice are starved for food and water for 18h and are then orally fed 1ml of 20% sucrose solution 
containing either 105 CFU (low feed) or 1010 CFU (high feed) of the E. coli strains of interest. 
After ingesting the bacterial suspension, both the food (Teklad mouse and rat diet; Harlan, 
Madison, WI) and streptomycin-water are returned to the mice, and fecal plate counts are 
determined with 1 g of feces collected after 5 h, 24 h, and on odd-numbered days. All bacterial 
concentrations are expressed as colony forming units (CFU) of the bacterium per gram of 
collected feces. Mice are housed individually in cages without bedding and are placed in clean 
cages at 24-h intervals. Each fecal sample is homogenized and diluted in 1 % Bacto-Tryptone 
(Difco), and then plated on MacConkey agar plates with appropriate antibiotics. MacConkey 
agar plates contain either streptomycin sulfate (100 μg/ml); streptomycin sulfate (100 μg/ml) 
and nalidixic acid (50 μg/ml); streptomycin sulfate (100 μg/ml) and chloramphenicol (30 μg/ml); 
or streptomycin sulfate (100 μg/ml) and rifampin (50 μg/ml). Streptomycin sulfate, 
chloramphenicol, and nalidixic acid are purchased from Sigma-Aldrich (St. Louis, MO). Rifampin 
is purchased from Fisher Scientific (Pittsburgh, PA). All plates are incubated for 18 to 48 h at 37 
°C prior to counting. 
Statistics. For each strain in the mice the log10 mean number of CFU per gram of feces plus or 
minus the standard error are calculated for each time point. A difference in all experiments 
between two strains of about 10-fold CFU/gram of feces (1 order of magnitude) is regarded as 
being statistically significant, if the P value is <0.05 using Student’s t test (two-tailed with 




The streptomycin-treated mouse model is well established for colonization experiments of 
Escherichia coli in the mouse large intestine and has been extensively used by Dr. Cohen’s 
laboratory group [9, 14, 17, 18, 43, 49, 59, 62]. The optimal colonization length has been 
established by Dr. Cohen’s laboratory as colonizing bacteria in the mouse large intestine during 
15 days for a short colonization experiment and 21 days for a long colonization experiment. 
Colonization experiments with an E. coli strain in the mouse large intestine during 15 days allows 
the analysis of their initiation and maintenance in the presence of strict anaerobes alone or also 
in the presence of another E. coli strain simultaneously fed to the mice. The rest of the 
facultative anaerobe members of the natural microflora can’t have an impact on the 
colonization experiment since they are removed from the large intestine by usage of 
streptomycin (5g/L) in the mice’s drinking water. Colonization experiments during a time period 
of 21 days is needed when an E. coli strain is fed ten days after precolonization of the mouse 
large intestine with a former fed E. coli strain. This shows how the late fed E. coli strain can 
compete against an established E. coli strain in the intestine. All colonizations are repeated at 
least once when not indicated differently. In the presence of discordant values for bacterial 
concentrations in one mouse, the colonization experiment is repeated as many times as needed 
to be able to recognize a clear behavior of the bacterial concentration throughout the 
experiment. 
4.1 Sequencing and growth of mutants in vitro. 
All mutants used in this study were sequenced at the University of Rhode Island Genomic and 
Sequencing Center and all generated deletions were in the expected places in the genome (data 
not shown). To test the in vitro ability to grow on certain substrates, each mutant was tested for 
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growth in M9 minimal medium containing 0.4% [v/v] glycerol, 0.4% [m/v] succinate, α-
ketoglutarate or acetate as the sole carbon and energy source. In glycerol as the only carbon 
source all mutants grow normally. All mutants having a ΔpckA ΔppsA double deletion failed to 
grow on succinate or on α-ketoglutarate as the sole carbon source. All mutants having a ΔaceA 
deletion failed to grow on acetate as the sole carbon source (data not shown). 
4.2 E. coli Nissle 1917 uses gluconeogenic substrates as well as glycolytic substrates to 
colonize the mouse large intestine, when it is the only strain fed to mice 
It was determined whether or not the gluconeogenic pathway is important for E. coli Nissle 1917 
to act as a probiotic strain and to prevent E. coli EDL933 from colonizing the mouse large 
intestine [33]. Gluconeogenesis is generally needed to regenerate the six carbon sugar glucose 
from gluconeogenic substrates such as pyruvate, TCA cycle intermediates, fatty acids and amino 
acids being converted into TCA cycle intermediates. To create an E. coli mutant which is not able 
to utilize gluconeogenesis in E. coli Nissle 1917 as well as in E. coli EDL933, both genes pckA (PEP 
carboxykinase) and ppsA (PEP synthetase) were knocked out simultaneously using the allelic 
recombination method by Wanner and Datsenko [12]. 
To determine if E. coli Nissle 1917 requires gluconeogenic or glycolytic nutrients to colonize the 
mouse large intestine when it is the only strain fed to mice, E. coli Nissle 1917 StrR ΔppsA 
ΔpckA::Cam was co-colonized with its parent strain (Figure 3). E. coli Nissle 1917 StrR NalR was 
simultaneously fed to mice at a low concentration (5.45 x 105 CFU/mouse) together with a low 
concentration (5.26 x 105 CFU/mouse) of E. coli Nissle 1917 StrR ΔppsA ΔpckA::Cam (Figure 3). 
Starting from day one of the colonization experiment both E. coli strains show a 101 CFU/gram of 
feces difference. Throughout the colonization in the mouse large intestine the difference 
between both E. coli strains becomes larger (102-103 CFU/gram of feces) and the number of E. 
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coli Nissle 1917 StrR ΔppsA ΔpckA::Cam at day fifteen ends of being 102 CFU/gram of feces 
lower than E. coli Nissle 1917 StrR NalR in the intestine. This experiment indicates that E. coli 
Nissle 1917 uses both glycolysis and gluconeogenesis to colonize the mouse large intestine, 
when it is the only E. coli strain present.  
4.3 E. coli EDL933 utilizes only glycolytic substrates when it is the only strain present during 
colonization of the mouse large intestine. 
Co-colonization of E. coli EDL933 StrR RifR and E. coli EDL933 StrR ΔppsA ΔpckA::Cam in the 
mouse large intestine shows that the colonization ability of both strains remains the same 
throughout the colonization when they are the only E. coli strain present (Figure 4). The wild 
type strain colonizes the mouse large intestine beginning from day one with a concentration of 
1.9 x 109 CFU/gram of feces, only tenfold higher than its mutant (1.9 x 108 CFU/gram of feces). 
Towards the end of the colonization both strains colonize the intestine with equal 
concentrations of 3.2 x 107 CFU/gram of feces (Figure 4). This result confirms the published data 
by Miranda et al. [42]. Since the gluconeogenic knockout mutant colonizes the intestine about 
as well as the wild type, it appears that E. coli EDL933 uses mainly glycolysis to maintain itself in 
the intestine and is not dependent on gluconeogenesis, when it is the only E. coli strain present.  
4.4 In the presence of precolonized E. coli Nissle 1917, E. coli EDL933 uses both glycolytic 
substrates and gluconeogenic substrates in order to colonize. 
It has been shown [42] that E. coli EDL933 switches from glycolytic substrates to gluconeogenic 
substrates when competing against E. coli MG1655 which only uses glycolytic substrates in order 
to maintain itself in the mouse large intestine.  
To answer the question as to whether E. coli Nissle 1917 uses up both glycolytic as well as 
gluconeogenic substrates and therefore is able to limit the colonization of E. coli EDL933 in the 
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intestine, both E. coli EDL933 strains, wild type simultaneously together with its gluconeogenic 
knockout mutant, were fed to mice precolonized with E. coli Nissle 1917 wild type (Figure 5), 
and in another colonization experiment with E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam, which is 
not able to use gluconeogenic substrates (Figure 6). Concentrating on the colonization result of 
competing against E. coli Nissle 1917 wild type (Figure 5), it is interesting that E. coli EDL933 wild 
type grew up to about 1.7 x 106 CFU/gram of feces whereas E. coli EDL933 StrR ΔpckA 
ΔppsA::Cam dropped down to numbers of below 102 CFU/gram of feces at day twenty-one. The 
difference of maintenance in the intestine between both E. coli EDL933 strains is therefore 104-
105 CFU/gram of feces towards the end of the colonization experiment. Competing against E. 
coli Nissle 1917 StrR ΔpckA ΔppsA::Cam only utilizing glycolysis (Figure 6), made it possible for E. 
coli EDL933 wild type to grow up to  1.4 x 107 CFU/gram of feces and therefore about an order of 
magnitude higher than competing against E. coli Nissle 1917 wild type. The difference of 
maintenance in the intestine between both E. coli EDL933 strains is 105-106 CFU/gram of feces 
towards the end of the colonization experiment. The fact that E. coli EDL933 StrR ΔpckA 
ΔppsA::Cam dropped down in both colonizations shows that E. coli Nissle 1917 uses up the 
majority of glycolytic substrates available in the mouse large intestine. E. coli EDL933 can 
therefore only grow up against E. coli Nissle 1917 when it utilizes both glycolysis and 
gluconeogenesis.  
4.5 E. coli EDL933 StrR ΔpckA ΔppsA::Cam is not limited by the presence of E. coli EDL933, 
but is outcompeted for nutrients by the presence of E. coli Nissle 1917 alone 
To determine whether E. coli EDL933 StrR ΔpckA ΔppsA::Cam was outcompeted in mice 
precolonized with either E. coli Nissle 1917 or E. coli Nissle StrR ΔpckA ΔppsA::Cam,  because of 
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the presence of the E. coli EDL933 wild type strain, both colonizations were repeated in the 
absence of E. coli EDL933.  
E. coli EDL933 StrR ΔpckA ΔppsA::Cam competing against precolonized E. coli Nissle 1917 (Figure 
7) was fed at day ten (3.8 x 103 CFU/gram of feces) and reached 4 x 103 CFU/gram of feces after 
one day. Afterwards it gradually decreased until on day fifteen it reached and stayed at about 70 
CFU/gram of feces throughout the end of the colonization. 
E. coli EDL933 StrR ΔpckA ΔppsA::Cam competing against precolonized E. coli Nissle 1917 StrR 
ΔpckA ΔppsA::Cam (Figure 8) was fed at day ten (4.4 x 104 CFU/gram of feces) and dropped 
gradually from the beginning on until it reached a low of 2 x 102 CFU/gram of feces on day 
fifteen. After that it came up and leveled off at around 1.5 x 103 CFU/gram of feces. 
In both cases, competing against precolonized E. coli Nissle wild type or Nissle StrR ΔpckA 
ΔppsA::Cam, E. coli EDL933 StrR ΔpckA ΔppsA::Cam dropped down to 102 (Figure 7) and 103 
CFU/gram of feces (Figure 8) respectively at day twenty-one. This indicates that, while 
competing against another E. coli strain such as E. coli Nissle 1917, the presence of E. coli 
EDL933 wild type doesn’t have much of an impact on E. coli EDL933 StrR ΔpckA ΔppsA::Cam 
struggle to maintain itself in the intestine. 
4.6 In the absence of E. coli Nissle 1917, the rest of the microbiota in the mouse large 
intestine doesn’t use up glycolytic substrates, which makes it possible for E. coli EDL933 
to grow to high numbers 
The question now was whether or not E. coli Nissle 1917 alone was responsible for using up all 
glycolytic and much of the gluconeogenic substrates, which keeps E. coli EDL933 down or does 
the anaerobic microbiota contribute? The colonization of E. coli EDL933 and E. coli EDL933 StrR 
ΔpckA ΔppsA::Cam being fed at day ten without precolonizing another E. strain (Figure 9), but 
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providing streptomycin containing drinking water throughout the whole colonization, creates 
clarity. The antibiotic streptomycin in the drinking water (5g/L) of the mice clears out all 
facultative anaerobes, which leaves a lot of nutrients behind, which can be used for incoming E. 
coli strains to get established in the intestine. The idea of this colonization was to test the effect 
of the rest of the microbiota in using up all nutrients during the first ten days of the colonization 
and then analyzing the reaction of both E. coli EDL933 and E. coli EDL933 StrR ΔpckA 
ΔppsA::Cam without the presence of anther E. coli strain. 
As shown in Figure 9 both E. coli EDL933 strains grew up to high numbers around 108-109 
CFU/gram of feces and remained on top of each other throughout the whole colonization 
experiment. Since wild type and mutant colonize all mice equally well, the microbiota doesn’t 
use up the nutrients available to E. coli in the intestine.  
4.7 Preliminary colonization experiments suggest that E. coli EDL933 uses gluconeogenic 
substrates in the presence of E. coli Nissle 1917 in order to colonize  
E. coli Nissle 1917 is colonized simultaneously with E. coli EDL933 and E. coli EDL933 StrR ΔpckA 
ΔppsA::Cam (Figure 10). Preliminary results show that all three E. coli strains enter the mouse 
large intestine at the same concentration of 2 x 104 CFU/gram of feces and grow up to high 
numbers. E. coli Nissle 1917 grows up and levels off at a concentration of between 109-1010 
CFU/gram of feces. Both E. coli EDL933 strains grow up to a concentration of around 2 x 108 
CFU/gram of feces and then gradually decrease until E. coli EDL933 wild type reaches a 
concentration 1.8 x 106 CFU/gram of feces and its gluconeogenic knockout mutant E. coli EDL933 
StrR ΔpckA ΔppsA::Cam drops down to a concentration of 3.9 x 102 CFU/gram of feces.   
The same ratio can also be shown when colonizing E. coli Nissle StrR ΔpckA ΔppsA::Cam 
colonizing simultaneously with E. coli EDL933 wild type and E. coli EDL933 StrR ΔpckA 
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ΔppsA::Cam (Figure 11). Preliminary results indicate that all E. coli strains enter the mouse large 
intestine at a similar concentration between 104-105 CFU/gram of feces. E. coli Nissle StrR ΔpckA 
ΔppsA::Cam grows up to numbers between 108-109 CFU/gram of feces and remains at these 
numbers throughout the colonization. E. coli EDL933 wild type first grows up even higher than E. 
coli Nissle 1917 StrR ΔpckA ΔppsA::Cam, but beginning at day five dramatically drops down in 
concentrations until it reaches a final concentration 6 x 107 CFU/gram of feces. Its gluconeogenic 
knockout mutant E. coli EDL933 StrR ΔpckA ΔppsA::Cam reaches its peak at day one with 5 x 107 
CFU/gram of feces and like the wild type dramatically  drops down to a concentration of 1.6 x 
104 CFU/gram of feces. It’s important to mention that 2 out of three mice died during the 
experiment, and therefore all data from day 6-15 are based on the fecal samples of only one 
mouse. Therefore this colonization result can only be interpreted as a preliminary result and 
needs to be repeated. 
Important in both colonizations is the fact that both E. coli EDL933 strains decreased in number, 
but the wild type always remains two or more orders of magnitude higher than the mutant. This 
suggests that E. coli EDL933 has an advantage in surviving in the mouse large intestine while 
competing against E. coli Nissle 1917. This advantage is the usage of gluconeogenesis.  Therefore 
E. coli EDL933 definitely switches to using gluconeogenesis in the presence of another E. coli 
strain in the intestine.  
4.8 E. coli Nissle 1917 relies on the usage of the glyoxylate shunt to colonize the mouse 
large intestine 
Knowing that E. coli EDL933 switches to gluconeogenesis in the presence of E. coli Nissle 1917, a 
further focus lies on acetate or fatty acids as gluconeogenic substrates, which are dependent on 
a functioning glyoxylate shunt. Therefore the aceA gene was knocked out using the gene 
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replacement method by Datsenko and Wanner to generate mutants which are not able to 
metabolize acetate or fatty acids. 
Figure 12 shows E. coli Nissle 1917 wild type concurrently fed to mice with E. coli Nissle 1917 
StrR ΔaceA:CamR. Both strains entered the mouse large intestine at a concentration of about 105 
CFU/gram of feces and grew up to numbers between 108-109 CFU/gram of feces. Beginning at 
day five E. coli Nissle 1917 StrR ΔaceA:CamR dropped down about an order of magnitude and 
stayed throughout the rest of the colonization about 1.5 orders of magnitude below the wild 
type.  This colonization shows that being able to utilize the glyoxylate shunt seems to be an 
advantage for E. coli Nissle 1917 in order to maintain itself in the intestine. 
4.9 Phenotypic characterization of the usage of different substrates in E. coli Nissle 1917 
and E. coli EDL933 strains 
The phenotypic metabolic GN2 MicroPlates were used to analyze the ability of a gram-negative 
bacterium, like E. coli, to utilize or oxidize compounds from a preselected panel of different 
carbon sources.  Concomitantly the purple dye tetrazolium violet is reduced and is detected by 
the OmniLog during a time frame of 48 hours. This assay results in a characteristic pattern of 
purple wells, called a metabolic fingerprint. Comparing the plates of two strains with each other, 
usage differences can be shown easily and repeatable. A closer look is taken at the wild type 
strains E. coli Nissle 1917 and E. coli EDL933 and their ΔpckA ΔppsA double knock-out mutant. 
Comparing the metabolic fingerprints of E. coli Nissle 1917 with that of E. coli Nissle 1917 StrR 
ΔpckA ΔppsA::Cam (Figure 13), it can be seen that the carbon sources in the wells showing 
more of a green color than red are more rapidly metabolized by the wild type than by the 
mutant (D5, D-galactonic acid lactone; E6, D,L-lactic acid). Carbon sources which could be 
metabolized only by the wild type and not by the gluconeogenic knockout mutant are 
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predominantly gluconeogenic substrates: C11, pyruvic acid methyl ester; C12, succinic acid 
mono-methyl ester; E12, succinic acid; F1, bromosuccinic acid; F4, L-alaninamide; F5, D-alanine; 
F6, L-alanine; F7, L-alanyl glycine; F8, L-asparagine; F9, L-aspartic acid; G6, L-proline; G8, D-
serine; G9, L-serine; H12, D-glucose 6-phosphate. The mutant doesn’t metabolize any of these 
95 carbon sources better than its wild type. 
Comparing E. coli EDL933 with E. coli EDL933 StrR ΔpckA ΔppsA::Cam (Figure 14), the carbon 
sources that are metabolized by only the wild type and not by the mutant are gluconeogenic 
substrates: C11, pyruvic acid methyl ester; D1, acetic acid; E6, D,L-lactic acid E8, propionic acid; 
F1, bromosuccinic acid; F5, D-alanine; F6, L-alanine; F7, L-alanyl glycine; G6, L-proline. The 
mutant metabolizes two carbon sources better than its wild type (B9, lactulose; H10, D,L,α-
glycerol phosphate). 
Comparing the metabolic fingerprints of E. coli Nissle 1917 and of E. coli EDL933 (Figure 15), the 
following carbon sources are metabolized exclusively by E. coli Nissle 1917: C6, D-sorbitol; D5, D-
galactonic acid lactone; E10, D-saccharic acid; F8, L-asparagine; F9, L-aspartic acid; G8, D-serine; 
G9, L-serine. E. coli Nissle 1917 metabolizes more rapidly but not exclusively the carbon sources: 
B9, lactulose; C5, L-rhamnose; C12, succinic acid mono-methyl ester; F1, bromosuccinic acid; 
E12, succinic acid; H10, D,L,α-glycerol phosphate. On the other hand E. coli EDL933 does better 
on carbon sources such as C4, D-raffinose; F3, glucoronamide; H2, inosine; H3, uridine; H4, 
thymidine. For three carbon sources E. coli EDL933 is the only metabolizing strain (C7, sucrose; 
D1, acetic acid; E8, propionic acid). However growth experiments in 1 x M9 with acetate as the 




Last but not least when comparing the metabolic ability of E. coli Nissle 1917 StrR ΔpckA 
ΔppsA::Cam and E. coli EDL933 StrR ΔpckA ΔppsA::Cam (Figure 16) there are differences to 
detect. E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam is the only strain metabolizing C6, D-sorbitol; 
D5, D-galactonic acid lactone; E6, D,L-lactic acid; E10, D-saccharic acid and metabolizes better 
the carbon source C5, L-rhamnose. E. coli EDL933 StrR ΔpckA ΔppsA::Cam metabolizes more 
rapidly the carbon sources: A8, N-acetyl-D-glucosamine; B8, α-D-lactose, C4, D-raffinose; F3, 
glucuronamide; H2, inosine; H3, uridine; H4, thymidine; H12, D-glucose 6-phosphate and is the 
only strain to metabolize C7, sucrose. 
4.10 Summary of the results 
According to the sequencing results of the University of Rhode Island Genomic and Sequencing 
Center all generated deletions were in the expected places in the genome (data not shown). In 
vitro experiments on the mutants’ ability to grow on certain carbon sources showed that 
gluconeogenic knockout mutants failed to grow on gluconeogenic substrates and glyoxylate 
shunt knockout mutants fail to grow on acetate as the sole carbon source.  
Analyzing all colonization experiments of the mouse large intestine, it was found that E. coli 
Nissle 1917 uses glycolytic substrates as well as gluconeogenic substrates to colonize the mouse 
large intestine, when it is the only strain fed to mice. E. coli EDL933 utilizes only glycolytic 
substrates when it is the only E. coli strain present in the intestine. In the presence of any other 
E. coli strain E. coli EDL933 switches from using glycolytic substrates to utilizing gluconeogenic 
substrates. If E. coli EDL933 and E. coli EDL933 StrR ΔpckA ΔppsA::Cam are fed to mice at the 
same time in the presence of E. coli Nissle 1917, E. coli EDL933 StrR ΔpckA ΔppsA::Cam seems to 
be not outcompeted due to the presence of E. coli EDL933, but due to the presence of E. coli 
Nissle 1917. This is supported by the colonization showing that in the absence of E. coli Nissle 
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1917, the rest of the microbiota in the mouse large intestine doesn’t use up glycolytic 
substrates.  
Focusing on the ability to use the glyoxylate shunt, E. coli Nissle 1917 relies on the usage of the 
glyoxylate shunt to colonize the mouse large intestine successfully. Phenotypic characterization 
of the usage of different substrates in E. coli Nissle 1917 and E. coli EDL933 strains shows 






Analysis of all generated mutants showed that all gene deletions are in the expected places in 
the genome (data not shown) according to the sequencing results of the University of Rhode 
Island Genomic and Sequencing Center. Therefore the created E. coli mutants are in fact the 
mutants which they are supposed to be.  In vitro experiments on the mutants’ ability to grow on 
certain carbon sources show that gluconeogenic knockout mutants fail to grow on 
gluconeogenic substrates and glyoxylate shunt knockout mutants fail to grow on acetate as the 
sole carbon source. This proves that the phenotypes of all mutants are correct as expected. 
In the gastrointestinal tract of mammals, Escherichia coli is the predominant facultative 
anaerobe [15], but makes up at most only 1 % of the microbiota [44].  
Based on colonization experiments of the streptomycin-treated mouse model several 
conclusions regarding the role of gluconeogenesis for growing in the mouse large intestine can 
be deduced.  E. coli Nissle 1917 colonizes the mouse large intestine 2.5 orders of magnitude 
better than E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam (Figure 3). This is an indicator for E. coli 
Nissle 1917 using glycolysis and gluconeogenesis concurrently, when it is the only strain present 
in the intestine. The wild type has the advantage of using both pathways at the same time and 
reaches concentrations of 108-109 CFU/gram of feces, whereas the mutant can only rely on using 
glycolysis and is therefore able to just grow up to numbers around 106 CFU/gram of feces. Co-
colonization of E. coli EDL933 and E. coli EDL933 StrR ΔpckA ΔppsA::Cam (Figure 4) shows that 
both colonize about equally well which indicates that E. coli EDL933 only uses glycolytic 
substrates when it is the only E. coli strain present in the mouse large intestine. When co-
colonized together with another E. coli strain such as E. coli Nissle 1917, E. coli EDL933 struggles 
to grow up to high numbers in the intestine, but compared to E. coli EDL933 StrR ΔpckA 
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ΔppsA::Cam it is growing at a significantly higher concentration (Figure 10, Figure 11, Figure 5 
and Figure 6). Therefore E. coli EDL933 needs the ability to utilize gluconeogenesis in order to be 
able to maintain itself in the intestine next to E. coli Nissle 1917. As described earlier E. coli 
EDL933 doesn’t need to use gluconeogenesis when it is the only strain in the intestine, but it 
needs to use gluconeogenesis in the presence of E. coli Nissle 1917.  
Further it was assumed that clearing out all facultative anaerobes of the intestine by providing 
streptomycin treated drinking water to the mice, and not adding E. coli during the first ten days 
would lead to an uptake of all available nutrients by the remaining microbiota in the intestine 
and when feeding E. coli EDL933 and E. coli EDL933 StrR ΔpckA ΔppsA::Cam  at day ten, they 
would have to overcome the depletion of nutrients. But contrary to expectations both E. coli 
EDL933 strains grow up to high numbers and co-colonized the intestine throughout the 
colonization experiment at a concentration of around 109 CFU/gram of feces. This shows that 
the remaining microbiota didn’t use up the glycolytic nutrients used by E. coli Nissle 1917. It is 
not clear if the microbiota is not able to metabolize the glycolytic substrates. It might also be 
possible that since this portion of the microbiota is made of strict anaerobes, they need a strict 
anaerobic environment to be able to survive. Because of the missing facultative anaerobes (E. 
coli) which would usually use up the oxygen, the concentration of strict anaerobes might 
decrease tremendously and this decrease of the anaerobic concentration could be the reason 
why the glycolytic substrates are not used up in the intestine. This result may suggest that, since 
the microbiota itself isn’t able to outcompete E. coli EDL933 in the mouse large intestine, a 
commensal E. coli strain such as the probiotic E. coli Nissle 1917 seems to be strongly needed to 
be able to nutritionally compete against E. coli EDL933.  
To conclude the results of all colonization experiments analyzing the effect of gluconeogenesis 
on colonization, it is suggested that E. coli EDL933 strongly relies on the usage of 
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gluconeogenesis in the presence of another E. coli strain in the intestine, since the ability to use 
glycolytic substrates is not enough for growing up. In case this other E. coli strain is able to use 
glycolysis and gluconeogenesis simultaneously, like E. coli Nissle 1917 does, this depletion of 
glycolytic and gluconeogenic substrates makes E. coli EDL933 struggle to be maintained in the 
intestine.  
Concentrating on the role of the glyoxylate shunt in E. coli for colonization and maintenance in 
the mouse large intestine, it was formerly shown that E. coli MG 1655 doesn’t rely on the usage 
of this pathway at all since the ΔaceA knockout mutant and the wild type colonize the intestine 
equally well [42]. Interesting here is that E. coli Nissle 1917 colonizes the intestine in average 
two orders of magnitudes higher than its ΔaceA mutant (Figure 12). This means that E. coli 
Nissle 1917 seems to rely on the glyoxylate shunt for colonizing the mouse large intestine. To 
compare the effect of the glyoxylate shunt on colonization of E. coli Nissle 1917 with that of E. 
coli EDL933, it might be interesting to generate an E. coli EDL933 ΔaceA knockout mutant and 
test its ability to colonize the intestine. 
Phenotypic characterization of the usage of different substrates in E. coli Nissle 1917 and E. coli 
EDL933 strains shows differences between both strains as well as between their gluconeogenic 
knockout mutants. All carbon sources which are gluconeogenic substrates, such as TCA cycle 
intermediates and amino acids, are shown to not be metabolized by the gluconeogenic 
knockout mutants, but by the wild type, which is expected. It is important to notice that E. coli 
Nissle 1917 uses carbon sources such as D-sorbitol, succinic acid, D-saccharic acid and amino 
acids like serine, aspartic acid and asparagine. Carbon sources important to mention which are 
more rapidly metabolized by E. coli EDL933 are sucrose, D-raffinose, propionic acid and acetic 
acid. The result that acetate is more rapidly metabolized by E. coli EDL933 is interesting. On the 
other hand it has been shown that the concentration of acetate in mouse cecal mucus in vivo is 
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just at the limit of detection (0.2 µM) [42], which suggests that acetate is unlikely as a major 
carbon source in the large intestine. 
Comparing the metabolic fingerprints of E. coli Nissle 1917 and E. coli Nissle 1917 StrR ΔpckA 
ΔppsA::Cam it is interesting to notice that the mutant is not better in metabolizing any of the 95 
carbon sources better than the wild type. The situation is different when comparing E. coli 
EDL933 and E. coli EDL933 StrR ΔpckA ΔppsA::Cam. The mutant is better than the wild type in 
metabolizing lactulose and D,L-α—glycerol phosphate. Whether these two carbon sources 
represent a nutritional niche for the mutant is not clear but the two strains co-colonize equally 
well. 
Most importantly the phenotypic characterization confirms the fact, that in contrast to the wild 
type, the gluconeogenic knockout mutant is not able to metabolize gluconeogenic substrates. 
Comparing E. coli Nissle 1917 and E. coli EDL933, there are no big differences in carbon source 
preferences of those carbon sources which are known to occur in the mucus layer of the mouse 




Pathogenic E. coli strains, EHEC, of the serotype O157:H7 are nowadays a major cause of 
foodborne disease, primarily in the United States, Canada, Japan, and Europe [25, 45]. It is 
important to find a treatment against these pathogenic bacteria. To do so, EHEC strains, such as 
E. coli EDL933 but also probiotic strains such as E. coli Nissle 1917 need to be further studied for 
example in terms of their way of action in the intestine, and their interaction when competing 
against each other. 
Colonization experiments in the streptomycin-treated mouse model of this study support the 
suggestion that E. coli EDL933 relies on the usage of gluconeogenesis in the presence of another 
E. coli strain, like E. coli Nissle 1917 (this study) or also the commensal E. coli MG1655 [42]. E. 
coli Nissle 1917 by itself being able to use glycolysis and gluconeogenesis simultaneously is able 
to keep E. coli EDL933 at relatively low levels when precolonized in the mouse large intestine. 
This effect is of even more severe as E. coli Nissle 1917 is able to outcompete the gluconeogenic 
knockout mutant E. coli EDL933 StrR ΔpckA ΔppsA::Cam down to a lower concentration or even 
to a complete loss from the intestine. Very important here is to further conduct a gene 
complementation of the ΔpckA ΔppsA mutation. Only when testing the mutant being restored 
to wild type will clearify whether or not the phenotypic defects of this mutant are only due to 
the knockout of the targeted genes. 
Based on the fact that E. coli EDL933 StrR ΔpckA ΔppsA::Cam is almost eliminated from the 
mouse large intestine competing against E. coli Nissle 1917 (Figure 5, Figure 6, Figure 7, Figure 
8), and based on the finding that E. coli EDL933 turns on virulence factors in a gluconeogenic 
environment [47], this leads to an hypothetical approach of defeating E. coli EDL933 in the 
intestine by finding a way to knockout the ability to use gluconeogenesis distictively in E. coli 
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EDL933. If this ability is taken away, E. coli EDL933 struggles to maintain in the mouse large 
intestine and therefore this might become a promising and effective treatment of EHEC related 
diseases. Based on several studies in which the intestine of newborns are colonized with E. coli 
Nissle 1917 and finding that this colonization supports their immune response to intestinal 
pathogens [26], this method of treatment right after birth might be a promising way of 





7 List of Abbreviations 
Abbreviation Meaning 
aceA gene coding for isocitrate lyase 
ATP Adenosine triphosphate 
CatR/CamR chloramphenicol resistance 
CFU Colony forming units 
E. coli Escherichia coli 
E. coli EDL933 the wild type strain of E. coli EDL933 
E. coli Nissle 1917 the wild type strain of E. coli Nissle 1917 
g gram 
GALT gut-associated lymphoid tissue 
L Liter 
LB Luria broth 
m mass 
PEP phosphoenolpyruvate 
pckA gene coding for  phosphoenolpyruvate carboxykinase 
ppsA gene coding for phosphoenolpyruvate synthetase 
RifR rifampin resistance 
SOB Super optimal broth 








Figure 3: Fifteen day colonization of E. coli Nissle 1917 wild type StrR NalR (■) and E. coli Nissle 
1917 StrR ΔpckA ΔppsA::Cam (♦). Two sets of three mice were each simultaneously fed 105 CFU 
of E. coli Nissle 1917 wild type StrR NalR and 105 CFU of E. coli Nissle 1917 StrR ΔpckA 
ΔppsA::Cam. At the indicated times, fecal samples were collected, homogenized, diluted and 
plated as described in the Materials and Methods. The log10 mean number of CFU per gram of 


























Figure 4: Fifteen day colonization of E. coli EDL933 wild type StrR RifR (■) and E. coli EDL933 StrR 
ΔpckA ΔppsA::Cam (♦). Two sets of three mice were each fed 105 CFU of E. coli EDL933 wild 
type StrR RifR. At day 10 E. coli EDL933 StrR ΔpckA ΔppsA::Cam were fed to the same mice. At the 
indicated times, fecal samples were collected, homogenized, diluted and plated as described in 
the Materials and Methods. The log10 mean number of CFU per gram of feces plus or minus the 



























Figure 5: Twenty-one day colonization of E. coli Nissle 1917 wild type StrR NalR (■), E. coli 
EDL933 wild type StrR RifR (♦) and E. coli EDL933 StrR ΔpckA ΔppsA::Cam (▲). Three sets of 
three mice were each fed 105 CFU of E. coli Nissle 1917 wild type StrR NalR. At day 10 105 CFU of 
E. coli EDL933 wild type StrR RifR and 105 CFU of E. coli EDL933 StrR ΔpckA ΔppsA::Cam were fed 
to the same mice. At the indicated times, fecal samples were collected, homogenized, diluted 
and plated as described in the Materials and Methods. The log10 mean number of CFU per gram 





Figure 6: Twenty-one day colonization of E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam (■), E. coli 
EDL933 wild type StrR RifR (♦) and E. coli EDL933 StrR ΔpckA ΔppsA::Cam (▲). Three sets of 
three mice were each fed 105 CFU of E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam. At day 10 105 
CFU of E. coli EDL933 wild type StrR RifR and 105 CFU of E. coli EDL933 StrR ΔpckA ΔppsA::Cam 
were fed to the same mice. At the indicated times, fecal samples are collected, homogenized, 
diluted and plated as described in the Materials and Methods. The log10 mean number of CFU 
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Figure 7: Twenty-one day colonization of E. coli Nissle 1917 wild type StrR NalR (■) and E. coli 
EDL933 StrR ΔpckA ΔppsA::Cam (♦). Two sets of three mice are each fed 105 CFU of E. coli 
Nissle 1917 wild type StrR NalR. At day 10 of the colonization, 105 CFU of E. coli EDL933 StrR 
ΔpckA ΔppsA::Cam were fed to the same mice. At the indicated times, fecal samples were 
collected, homogenized, diluted and plated as described in the Materials and Methods. The log10 





























Figure 8: Twenty-one day colonization of E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam (■) and E. 
coli EDL933 StrR ΔpckA ΔppsA::Cam (♦). Two sets of three mice are each fed 105 CFU of E. coli 
Nissle StrR ΔpckA ΔppsA::Cam. At day 10 of the colonization, 105 CFU of E. coli EDL933 StrR 
ΔpckA ΔppsA::Cam were fed to the same mice. At the indicated times, fecal samples were 
collected, homogenized, diluted and plated as described in the Materials and Methods. The log10 



























Figure 9: Twenty-one day colonization of E. coli EDL933 (■) and E. coli EDL933 StrR ΔpckA 
ΔppsA::Cam (♦).At day 10 of the colonization, 105 CFU of E. coli EDL933 and E. coli EDL933 StrR 
ΔpckA ΔppsA::Cam were fed simultaneously to two sets of three mice. At the indicated times, 
fecal samples were collected, homogenized, diluted and plated as described in the Materials and 
Methods. The log10 mean number of CFU per gram of feces plus or minus the standard error is 


























Figure 10: Fifteen day colonization of E. coli Nissle 1917 StrR NalR (■), E. coli EDL933 (♦) and E. 
coli EDL933 StrR ΔpckA ΔppsA::Cam (▲). One set of three mice was simultaneously fed 105 
CFU of E. coli Nissle 1917 StrR NalR, E. coli EDL933 and E. coli EDL933 StrR ΔpckA ΔppsA::Cam. At 
the indicated times, fecal samples were collected, homogenized, diluted and plated as described 
in the Materials and Methods. The log10 mean number of CFU per gram of feces plus or minus 
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Figure 11: Fifteen day colonization of E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam (■), E. coli 
EDL933 (♦) and E. coli EDL933 StrR ΔpckA ΔppsA::Cam (▲). One set of three mice were 
simultaneously fed 105 CFU of E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam, E. coli EDL933 and E. 
coli EDL933 StrR ΔpckA ΔppsA::Cam. Two mice died during the experiment each on day five and 
day six, therefore all data from day 6-15 are based on the fecal samples of only one mouse. At 
the indicated times, fecal samples were collected, homogenized, diluted and plated as described 
in the Materials and Methods. The log10 mean number of CFU per gram of feces plus or minus 
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Figure 12: Fifteen day colonization of E. coli Nissle 1917 wild type StrR NalR (■) and E. coli Nissle 
1917 StrR ΔaceA:CamR (♦). Two sets of three mice were each simultaneously fed 105 CFU of E. 
coli Nissle 1917 wild type StrR NalR and 105 CFU of E. coli Nissle 1917 StrR ΔaceA:CamR. At the 
indicated times, fecal samples were collected, homogenized, diluted and plated as described in 
the Materials and Methods. The log10 mean number of CFU per gram of feces plus or minus the 


























Figure 13: Phenotypic assay results for E. coli Nissle 1917 wild type StrR NalR (green) compared 
to E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam (red). Biolog GN2 plates (gram negative carbon 
nutrition) are utilized to analyze the overall metabolic capacity to consume 95 individual carbon 
sources (for details see Material and Methods). Each well shows a kinetic curve plotting 
substrate vs. time (48hours). Green represents carbon source utilization by the E. coli Nissle 
1917 wild type strain, red represents the mutant strain, and yellow represents carbon utilization 







Figure 14: Phenotypic assay results for E. coli EDL933 wild type StrR RifR (green) compared to E. 
coli EDL933 StrR ΔpckA ΔppsA::Cam (red). Biolog GN2 plates (gram negative carbon nutrition) 
are utilized to analyze the overall metabolic capacity to consume 95 individual carbon sources 
(for details see Material and Methods). Each well shows a kinetic curve plotting substrate vs. 
time (48hours). Green represents carbon source utilization by the E. coli EDL933 wild type strain, 








Figure 15:  Phenotypic assay results for E. coli Nissle 1917 wild type StrR NalR (green) compared 
to E. coli EDL933 wild type StrR RifR (red). Biolog GN2 plates (gram negative carbon nutrition) 
are utilized to analyze the overall metabolic capacity to consume 95 individual carbon sources 
(for details see Material and Methods). Each well shows a kinetic curve plotting substrate vs. 
time (48hours). Green represents carbon source utilization by the E. coli Nissle 1917 wild type 










Figure 16: Phenotypic assay results for E. coli Nissle 1917 StrR ΔpckA ΔppsA::Cam (green) 
compared to E. coli EDL933 StrR ΔpckA ΔppsA::Cam (red). Biolog GN2 plates (gram negative 
carbon nutrition) are utilized to analyze the overall metabolic capacity to consume 95 individual 
carbon sources (for details see Material and Methods). Each well shows a kinetic curve plotting 
substrate vs. time (48hours). Green represents carbon source utilization by the E. coli Nissle 
1917 StrR ΔpckA ΔppsA :: Cam strain, red represents E. coli EDL933 StrR ΔpckA Δpps::Cam strain, 
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